



Aranesp, Epogen, Procrit, Retacrit

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462
(800.88.CIGNA)

| PHYSICIAN INFORMATION | | | PATIENT INFORMATION | | |
|---|--------------------|------|--|------------------|------|
| * Physician Name: | | | *Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.* | | |
| Specialty: | * DEA, NPI or TIN: | | | | |
| Office Contact Person: | | | * Patient Name: | | |
| Office Phone: | | | * Cigna ID: | * Date of Birth: | |
| Office Fax: | | | * Patient Street Address: | | |
| Office Street Address: | | | City: | State: | Zip: |
| City: | State: | Zip: | Patient Phone: | | |
| Urgency: <input type="checkbox"/> Standard <input type="checkbox"/> Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function) | | | | | |
| Medication requested: <input type="checkbox"/> Aranesp <input type="checkbox"/> Epogen <input type="checkbox"/> Procrit <input type="checkbox"/> Retacrit <input type="checkbox"/> Other (please specify): Strength: _____ Dosing schedule: _____ J-Code: _____ ICD10: _____ Number of Injections per month: _____ Expected duration: _____ Patient's weight: _____ | | | | | |
| Where will this medication be obtained? <input type="checkbox"/> Accredo Specialty Pharmacy** <input type="checkbox"/> Home Health / Home Infusion vendor <input type="checkbox"/> Hospital Outpatient <input type="checkbox"/> Physician's office stock (billing on a medical claim form) <input type="checkbox"/> Retail pharmacy <input type="checkbox"/> Other (please specify): **Cigna's nationally preferred specialty pharmacy | | | | | |
| **Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822 NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557 | | | | | |
| Facility and/or doctor dispensing and administering medication: Facility Name: _____ State: _____ Tax ID#: _____ Address (City, State, Zip Code): _____ | | | | | |
| Where will this drug be administered? <input type="checkbox"/> Patient's Home <input type="checkbox"/> Physician's Office <input type="checkbox"/> Hospital Outpatient <input type="checkbox"/> Other (please specify): _____ | | | | | |
| NOTE: Per some Cigna plans, infusion of medication MUST occur in the least intensive, medically appropriate setting. Is this patient a candidate for re-direction to an alternate setting (such as alternate infusion site, physician's office, home) with assistance of a Specialty Care Options Case Manager? <input type="checkbox"/> Yes <input type="checkbox"/> No (provide medical necessity rationale): _____ | | | | | |
| Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? <input type="checkbox"/> Yes <input type="checkbox"/> No | | | | | |
| Clinical Data: Is this drug being used to treat anemia related to any of the following? <input type="checkbox"/> anemia due to acute blood loss <input type="checkbox"/> anemia due to chemotherapy <input type="checkbox"/> anemia due to chronic kidney disease (CKD) WITH dialysis <input type="checkbox"/> anemia due to chronic kidney disease (CKD) WITHOUT dialysis <input type="checkbox"/> anemia due to hepatitis C treatment <input type="checkbox"/> anemia due to myelodysplastic syndrome (MDS) <input type="checkbox"/> anemia due to myelofibrosis (MF) <input type="checkbox"/> anemia due to prematurity <input type="checkbox"/> anemia due to radiotherapy in cancer <input type="checkbox"/> anemia due to zidovudine treatment <input type="checkbox"/> to reduce the need of allogeneic red blood cell transfusions in a patient undergoing surgery <input type="checkbox"/> none of the above (please specify): _____ | | | | | |

Is this a new start or continuation of therapy? If your patient has already begun treatment with drug samples or is a restart of therapy, please choose "new start of therapy". new start of therapy continued therapy- start date:

(if requesting Epogen) Which of the following is true for your patient in regards to brand Procrit?

- The patient is able to try brand Procrit, but has not done so yet
- The patient tried brand Procrit, but they did not tolerate it.
- other

(if CKD, hepatitis C, preoperative, zidovudine) Which of the following applies to your patient?

- patient's serum ferritin is 100 mcg/L or higher
- patient's serum transferrin saturation is 20% or higher
- neither of the above
- unknown

(if chemo, MDS, or MF) Which of the following applies to your patient?

- Patient's serum ferritin is 30 mcg/L or higher
- Patient's serum transferrin saturation is 20% or higher
- neither of the above
- unknown

(if neither/unknown to either of the 2 previous questions) Please provide current lab levels to support that your patient has adequate iron stores (transferrin, ferritin, and transferrin saturation), including dates of draws.

What is/was your patient's PRETREATMENT hemoglobin level (g/dL) [prior to use of epoetin (Aranesp, Epogen, Procrit, Retacrit)]?

(if **chemotherapy**, **MDS** or **MF**, continued therapy) Please provide a hemoglobin level (g/dL) for your patient taken within the first 12 weeks of therapy with epoetin and include the date the lab was drawn.

(if **CKD** or **preoperative**, continued therapy) Please provide a recent hemoglobin level (g/dL) for your patient while on therapy with epoetin and include the date the lab was drawn.

(if **hepatitis C** or **zidovudine**, continued therapy) Please provide a hemoglobin level (g/dL) for your patient taken within the first 6 months of therapy with epoetin and include the date the lab was drawn.

(if **chemotherapy**) Is your patient being treated for either AML or CML (acute myeloid leukemia or chronic myeloid leukemia)?

Yes No

(if **chemotherapy**) Is your patient receiving palliative chemotherapy?

Yes No

(if **chemotherapy**) Is your patient currently receiving myelosuppressive chemotherapy treatments?

Yes No

(if yes) Is chemotherapy expected to continue for at least 2 more months (8 weeks)?

Yes No

How many more weeks of chemotherapy are planned? _____

(if chemo) Is the anticipated outcome of myelosuppressive chemotherapy to cure?

Yes No

(if **hepatitis C**) How many more weeks of hepatitis C therapy is your patient expected to receive? _____

(if **hepatitis C**) Is your patient currently receiving ribavirin in combination with either interferon alfa (Intron A) or peginterferon alfa

(Pegasys, PegIntron)?

Yes No

(if **MDS** or **MF**) What is/was your patient's PRETREATMENT erythropoietin level [prior to use of epoetin (Aranesp, Epogen, Procrit, Retacrit)]? _____

(if **MDS** or **MF**, continued therapy) What is your patient's current hemoglobin level and date of lab draw? _____

(if **preoperative**, continued therapy) Please explain the clinical rationale for your patient to continue epoetin, including surgery date.

(if **preoperative**) Is anemia secondary to autologous blood donation (patient self-donated blood)?

Yes No

(if preoperative) Is your patient not willing or not able to donate autologous blood prior to surgery?

Yes No

(if **preoperative**) Is your patient scheduled for elective surgery?

Yes No

(if **preoperative**) Is your patient scheduled for cardiac or vascular surgery?

Yes No

(if no/unknown) What kind of surgery is your patient scheduled to undergo? _____

(if zidovudine) Is your patient currently receiving zidovudine (Retrovir) treatment?

Yes No

Additional Pertinent Information:

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature: _____ **Date:** _____

Save Time! Submit Online at: www.covermy meds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v010124

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005